Dysphagia Knowledge Hub — 吞嚥困難知識庫

Expiratory Muscle Strength Training (EMST) for Dysphagia

Expiratory Muscle Strength Training (EMST) is one of the most rigorously studied dysphagia interventions of the past two decades. Unlike traditional swallowing exercises that target the tongue or pharynx directly, EMST works through a clever piece of biomechanics: the same submental and suprahyoid muscles that elevate the hyolaryngeal complex during a swallow are also recruited during forceful exhalation. Train one, and you measurably strengthen the other. This guide explains the evidence, the standard protocol, device selection, patient populations, contraindications, and how speech-language pathologists and caregivers implement EMST safely at home.

What Is EMST?

EMST is a resistance training program that uses a calibrated, spring-loaded threshold device. The patient inhales deeply, then exhales forcefully through a mouthpiece against a pre-set pressure threshold. The valve only opens when the patient generates enough expiratory pressure to overcome the calibrated spring; below that threshold, no airflow passes. This forces a true, supra-threshold contraction of expiratory and accessory respiratory muscles every breath — the same overload principle used in skeletal muscle resistance training in any gym.

The dysphagia connection is anatomical. The submental muscle group (anterior belly of digastric, mylohyoid, geniohyoid) and the suprahyoid muscles play a dual role: they pull the hyolaryngeal complex upward and forward during swallowing (protecting the airway and opening the upper esophageal sphincter), and they stabilize the upper airway and contribute to forced expiration. Studies using surface electromyography (sEMG) have confirmed that submental activation during EMST is comparable to activation during effortful swallow maneuvers. This is why EMST is classified as an indirect swallowing exercise — it never asks the patient to swallow during training, but it strengthens the very muscles that protect the airway during every swallow.

The Standard Protocol: 5 × 5 × 5

The protocol popularized by the University of Florida group (Sapienza, Troche, Hegland, and colleagues) and now considered the field standard is straightforward:

5 sets of 5 breaths per session = 25 effortful breaths per day
5 days per week
4 to 5 weeks minimum to produce measurable change in swallow safety
Resistance set at 75% of Maximum Expiratory Pressure (MEP) measured by a manometer at baseline; some protocols use 50–75% depending on patient frailty
Re-titrate weekly — as the patient’s MEP rises, the device threshold is increased to maintain the 75% relative load

A typical clinic session takes only 5–10 minutes once the patient is trained, which is part of why adherence rates in published trials are unusually high for a swallowing exercise. Patients can complete the full daily dose in three or four short bouts spread across the day.

Evidence Base by Population

Parkinson’s Disease — The Strongest Evidence

The pivotal randomized controlled trial by Troche and colleagues (2010, Neurology) demonstrated that 4 weeks of EMST in 60 patients with Parkinson’s disease produced significant reductions in Penetration-Aspiration Scale (PAS) scores on videofluoroscopy compared with sham training. Hyolaryngeal excursion improved measurably, and patients showed gains in voluntary cough strength — a critical secondary benefit because effective cough is the last line of defense when aspiration does occur. EMST is now embedded in many movement disorder clinics’ standard care for mild-to-moderate PD with documented dysphagia.

Stroke

A 2016 randomized controlled trial (Park et al., Journal of Oral Rehabilitation) in 27 subacute stroke patients with oropharyngeal dysphagia found that 4 weeks of EMST improved Functional Dysphagia Scale and PAS scores significantly more than sham training. Subsequent systematic reviews confirm a positive effect on hyoid displacement and airway protection in stroke survivors, although clinicians typically wait until medical stability is achieved (usually beyond the hyperacute phase) before initiating resistance training.

Head and Neck Cancer

A 2025 prospective pilot trial in disease-free head and neck cancer survivors with radiation-associated dysphagia put 30 participants through an 8-week EMST protocol (25 reps, 5 days/week). The intervention was feasible and safe, with measurable improvements in expiratory pressure and swallowing function. Importantly, EMST does not appear to exacerbate radiation fibrosis, making it one of the few resistance options available to this population, where direct lingual or pharyngeal exercise can be limited by trismus, mucositis, or fibrotic tissue.

Progressive Supranuclear Palsy and Atypical Parkinsonisms

A 2025 feasibility study in Neurodegenerative Disease Management showed that EMST is feasible for most people with PSP, though clinician supervision is often required because of cognitive and oculomotor limitations that make independent device use harder. Effect sizes in PSP are smaller than in idiopathic PD, but the intervention remains worth offering given the otherwise limited options.

Dementia and Critical Illness Survivors

A 2024 case report demonstrated that EMST was feasible, well-tolerated, and potentially efficacious in a patient with mixed dementia and oropharyngeal dysphagia — challenging the assumption that cognitive impairment automatically excludes patients from active rehabilitation. A systematic review protocol registered in late 2024 is currently examining EMST in survivors of critical illness, a population at high risk for ICU-acquired weakness affecting respiratory and swallowing musculature.

Healthy Older Adults

Several studies (Kim et al., Hutcheson et al.) have shown that EMST produces gains in swallowing biomechanics even in community-dwelling older adults without diagnosed dysphagia — suggesting a possible role in prevention of presbyphagia-related decline, though this remains an emerging indication rather than standard practice.

Choosing a Device

The most widely used and validated device is the EMST150 (manufactured by Aspire LLC). It is a spring-loaded threshold device adjustable from 30 to 150 cm H₂O in 5 cm H₂O increments, costs approximately USD $50–70, and is the device used in the majority of published trials. Key features clinicians look for:

Calibrated resistance: a true threshold valve, not a flow-resistive device. Flow resistors (used in some inspiratory training products) are not equivalent and have not been validated for dysphagia.
Adjustable across the clinical range: most adult patients fall between 40 and 90 cm H₂O. A device that maxes out at 60 will become useless within weeks for an improving patient.
Simple, durable mouthpiece: bite blocks help patients with poor lip seal — a common issue in PD and stroke.

Generic threshold devices marketed for athletic respiratory training (e.g., POWERbreathe, Threshold PEP) may produce some training effect but are not the validated tool. For clinical dysphagia indications, use a device with published trial data.

Contraindications and Cautions

EMST is generally well-tolerated, but several conditions warrant caution or outright contraindication:

Untreated pulmonary disease with active exacerbation (severe COPD, asthma in flare, pneumonia)
Unstable cardiovascular disease, recent myocardial infarction, or uncontrolled hypertension — the Valsalva-like pressures generated during forceful expiration can transiently elevate intrathoracic and blood pressure
Recent abdominal or thoracic surgery, untreated hernia, or recent rib fracture
Untreated pneumothorax or active barotrauma
Severe cognitive impairment that prevents the patient from understanding the breath cycle (relative contraindication — supervised training may still work)
Tracheostomy with cuff inflated — capping or speaking valve trials require separate clearance

Clinicians should obtain a baseline MEP and ideally a pulmonary clearance for high-risk patients before starting. Mild dizziness or transient headache during the first sessions is common and usually resolves with pacing — instruct patients to rest for 30 seconds between sets.

How EMST Fits with Other Dysphagia Interventions

EMST is not a replacement for direct swallowing therapy; it is a complement. A typical evidence-based program for, say, a patient with mild Parkinson’s disease and documented penetration on videofluoroscopy might combine:

EMST at 75% MEP, 5×5×5, daily — for hyolaryngeal elevation and cough strength
Effortful swallow or Mendelsohn maneuver — for direct pharyngeal training during meals
Lee Silverman Voice Treatment (LSVT LOUD) — for the laryngeal and respiratory coordination dimension
Postural compensations (chin tuck where indicated by VFSS findings)
Diet texture modification per IDDSI recommendations as a safety bridge during training

EMST and the McNeill Dysphagia Therapy Program (MDTP) can also be combined sequentially, and there is preliminary evidence that pairing EMST with neuromuscular electrical stimulation (NMES) may produce additive effects, though this combination is not yet standardized.

Practical Implementation: A 4-Week Home Protocol

Once an SLP has set the resistance level (typically after a baseline MEP measurement on a digital manometer such as the MicroRPM):

Week 1

Settings: 75% of baseline MEP
Dose: 5 sets × 5 breaths, 5 days
Goal: develop technique — full inhalation, lip seal, single forceful exhalation per breath
Common issue: cheek puffing instead of true diaphragmatic engagement; coach the patient to feel abdominal contraction

Week 2

Re-measure MEP at start of week; adjust device if MEP rose by ≥10 cm H₂O
Same dose as Week 1
Monitor for fatigue, dizziness, or chest discomfort

Week 3

Re-titrate
Patients with reasonable adherence often report easier coughing and clearing of throat secretions by this point

Week 4

Re-titrate
Final outcome measures: repeat MEP, repeat clinical swallow exam (and ideally instrumental — VFSS or FEES — if accessible), Voluntary Cough peak flow

Patients who respond well typically continue a maintenance dose of 25 breaths, 3 days per week, indefinitely, particularly in progressive conditions like Parkinson’s disease where ongoing training offsets disease progression.

When EMST Is Not the Right Answer

Despite strong evidence in its target populations, EMST is not universally indicated:

Pure esophageal dysphagia (achalasia, strictures, eosinophilic esophagitis) — EMST works on oropharyngeal mechanisms; esophageal-stage problems require gastroenterology workup
Mechanical obstruction (Zenker diverticulum, large osteophytes, tumor) — surgical/procedural treatment is primary
End-of-life palliative care where comfort, not function, is the goal
Patients with no measurable expiratory weakness and no airway protection deficit — EMST is targeted therapy, not a generic add-on

A thorough instrumental swallowing assessment (VFSS or FEES) before starting EMST helps ensure the patient’s specific deficit profile matches what EMST treats: hyolaryngeal elevation, airway closure timing, and cough function.

Summary for Clinicians and Caregivers

EMST occupies a rare position in dysphagia rehabilitation: it has Level 1 evidence in Parkinson’s disease, growing evidence across stroke, head and neck cancer, PSP, dementia, and critical illness survivors, a clear and reproducible protocol, low cost, excellent home-program feasibility, and a favorable safety profile. For SLPs, integrating EMST into routine practice for appropriate patients is now considered standard of care in many centers. For caregivers, supervising 5 to 10 minutes of EMST a day is one of the higher-yield interventions you can support — especially when combined with mealtime safety strategies and routine oral care.

Sources: